Bristol-Myers Squibb: oral psoriais drug shows efficacy
(CercleFinance.com) - Bristol-Myers Squibb said its experimental psoriasis drug showed a significant reduction in disease activity in patients in a mid-stage trial.
In a Phase 2 study on the group's investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor BMS-986165, efficacy endpoints, including over 75% and 90% reduction in the psoriasis area and severity index, were achieved following 12 weeks of treatment in patients with moderate-to-severe plaque psoriasis, Bristol said.
Nasopharyngitis, headache, diarrhea, nausea and upper respiratory tract infection were the most common adverse events reported, it added.
Patients with psoriasis currently have a limited number of oral therapies available, according to physicians.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a Phase 2 study on the group's investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor BMS-986165, efficacy endpoints, including over 75% and 90% reduction in the psoriasis area and severity index, were achieved following 12 weeks of treatment in patients with moderate-to-severe plaque psoriasis, Bristol said.
Nasopharyngitis, headache, diarrhea, nausea and upper respiratory tract infection were the most common adverse events reported, it added.
Patients with psoriasis currently have a limited number of oral therapies available, according to physicians.
Copyright (c) 2018 CercleFinance.com. All rights reserved.